← Leaderboards
Travis Nemkov
Sinopia Biosciences, Inc.
$2,072,523
Attributed
$4,145,045
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2018–22$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$4,145,045 · 3
By mechanism
R44$3,702,618 · 2
R43$442,427 · 1
Top collaborators
- Aarash Bordbar3 shared
- Tatsuro Yoshida2 shared
Most similar at Sinopia Biosciences, Inc.
Same institution · by research overlap
- Aarash Bordbar$10,092,533
Others in their field
Other Emerging Leaders on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$211,662,224
Research focus
BaseTechnologyMetabolomicsSamplingScreeningGenerationsExposure ToMetabolicGrantResponsePlasmaPre-ClinicalInterestEvaluationFundingDoseDrug DevelopmentBiochemicalDrug DiscoveryAutomationCell LineEmerging TechnologiesCouplingCost
Grant awards (5)
Development of a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery$871,587
R44 · FY2022 · GM
Development of a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery$1,335,997
R44 · FY2021 · GM
An additive solution optimized for anaerobic (hypoxic) RBC storage to minimize storage lesion development.$773,178
R44 · FY2021 · HL
An additive solution optimized for anaerobic (hypoxic) RBC storage to minimize storage lesion development.$721,856
R44 · FY2020 · HL
Development of a metabolomics and machine learning based high-throughput screening platform for data-driven drug discovery$442,427
R43 · FY2018 · GM